RS-001

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameRS-001
Drug Alias NameCD19-CAR-mbIL15-DNT Cells therapy(Wyze Biotech)RS001RS-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWyze Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWyze Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A